$2.86 Billion is the total value of Avidity Partners Management LP's 93 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | GE HEALTHCARE TECHNOLOGIES I | $84,928,296 | – | 1,045,400 | +100.0% | 2.97% | – | |
| ABBV | New | ABBVIE INC | $69,844,032 | – | 518,400 | +100.0% | 2.44% | – |
| LLY | New | LILLY ELI & CO | $62,374,340 | – | 133,000 | +100.0% | 2.18% | – |
| MCK | New | MCKESSON CORP | $43,243,772 | – | 101,200 | +100.0% | 1.51% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $42,698,570 | – | 468,700 | +100.0% | 1.49% | – |
| PFE | New | PFIZER INC | $40,988,690 | – | 1,117,467 | +100.0% | 1.43% | – |
| IMGN | New | IMMUNOGEN INC | $37,698,486 | – | 1,997,800 | +100.0% | 1.32% | – |
| PRVA | New | PRIVIA HEALTH GROUP INC | $28,193,735 | – | 1,079,806 | +100.0% | 0.98% | – |
| BAX | New | BAXTER INTL INC | $27,550,132 | – | 604,700 | +100.0% | 0.96% | – |
| BPMC | New | BLUEPRINT MEDICINES CORP | $26,228,000 | – | 415,000 | +100.0% | 0.92% | – |
| EDIT | New | EDITAS MEDICINE INC | $24,690,000 | – | 3,000,000 | +100.0% | 0.86% | – |
| LNTH | New | LANTHEUS HLDGS INC | $20,568,792 | – | 245,100 | +100.0% | 0.72% | – |
| New | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $20,400,000 | – | 400,000 | +100.0% | 0.71% | – | |
| AXNX | New | AXONICS INC | $19,163,459 | – | 379,700 | +100.0% | 0.67% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $18,530,050 | – | 481,300 | +100.0% | 0.65% | – |
| New | ROIVANT SCIENCES LTD | $17,010,000 | – | 1,687,500 | +100.0% | 0.59% | – | |
| CERE | New | CEREVEL THERAPEUTICS HLDNG I | $15,933,148 | – | 501,200 | +100.0% | 0.56% | – |
| New | ACELYRIN INC | $15,675,000 | – | 750,000 | +100.0% | 0.55% | – | |
| SDGR | New | SCHRODINGER INC | $13,723,008 | – | 274,900 | +100.0% | 0.48% | – |
| New | 2SEVENTY BIO INC | $13,581,040 | – | 1,342,000 | +100.0% | 0.47% | – | |
| NARI | New | INARI MED INC | $10,174,500 | – | 175,000 | +100.0% | 0.36% | – |
| DNLI | New | DENALI THERAPEUTICS INC | $8,344,012 | – | 282,752 | +100.0% | 0.29% | – |
| ATEC | New | ALPHATEC HLDGS INC | $7,066,140 | – | 393,000 | +100.0% | 0.25% | – |
| GRTS | New | GRITSTONE BIO INC | $5,392,725 | – | 2,765,500 | +100.0% | 0.19% | – |
| SCYX | New | SCYNEXIS INC | $5,129,265 | – | 1,738,734 | +100.0% | 0.18% | – |
| SLP | New | SIMULATIONS PLUS INC | $1,988,847 | – | 45,900 | +100.0% | 0.07% | – |
| BHC | New | BAUSCH HEALTH COS INC | $1,720,800 | – | 215,100 | +100.0% | 0.06% | – |
| New | STRUCTURE THERAPEUTICS INCsponsored ads | $1,571,346 | – | 37,800 | +100.0% | 0.06% | – | |
| New | EXSCIENTIA PLCads | $755,392 | – | 127,600 | +100.0% | 0.03% | – | |
| New | ARTERIS INC | $514,910 | – | 75,500 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 15 | Q3 2023 | 4.6% |
| ARVINAS INC | 14 | Q3 2023 | 4.9% |
| ZENTALIS PHARMACEUTICALS INC | 14 | Q3 2023 | 4.8% |
| SYNDAX PHARMACEUTICALS INC | 14 | Q3 2023 | 3.2% |
| IDEAYA BIOSCIENCES INC | 13 | Q3 2023 | 2.5% |
| NATERA INC | 13 | Q3 2023 | 1.9% |
| ALPINE IMMUNE SCIENCES INC | 13 | Q3 2023 | 0.5% |
| ABBVIE INC | 12 | Q2 2023 | 9.7% |
| HORIZON THERAPEUTICS PUB LTD | 12 | Q3 2022 | 3.4% |
| AVANTOR INC | 11 | Q1 2023 | 6.0% |
View Avidity Partners Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2023 | 1,888,887 | 4.0% |
| ESSA Pharma Inc. | February 14, 2023 | 1,855,400 | 4.2% |
| Gritstone bio, Inc. | February 14, 2023 | 2,859,971 | 3.3% |
| IVERIC bio, Inc. | February 14, 2023 | 838,407 | 0.6% |
| ONCOSEC MEDICAL IncSold out | February 14, 2023 | 0 | 0.0% |
| PhaseBio Pharmaceuticals Inc | February 14, 2023 | 2,040,000 | 4.1% |
| Phathom Pharmaceuticals, Inc. | February 14, 2023 | 1,900,000 | 4.6% |
| Viridian Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Anika Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Avidity Partners Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| SC 13G | 2024-04-09 |
| SC 13G | 2024-03-27 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
View Avidity Partners Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.